**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Wilson Marques Junior
FMRP-USP
Ribeirão Preto, SP, Brazil

**Main Body of the Abstract**
Introduction: Although characterized as a Portuguese descent country, the Brazilian population is multi racial, including mainly Portuguese and African descents, but also Italians, Spanish, Japanese, Germans and Dutch, with minor contribution of other countries.  Due to the huge Portuguese importance, the TTRVal50Met was thought to be the only mutation, but this concept gradually changed. In this study we characterized the distribution of ATTRv in Brazil and its ethnical aspects.
Methods: This cohort was descriptive, retrospective and enrolled a group of patients harboring suggestive phenotypes and at-risk family members of index cases with the TTR pathogenic mutation from 19 Brazilian centers.
Results: We enrolled a total of 784 patients belonging to 261 families. 385 (49,1%) were male. The disease was manifest in 435 (55,5%) of patients and one third (33,3%) were asymptomatic carriers (11,2% unknown). The three most frequent TTR mutation were TTRpVal50Met (53,6%), TTRpVal142Ile (31,6%) and TTRIle127Val (8,4%). Other 13 mutations account for equal or less than 1% (Ala60Thr, Arg123His, Asp58Ala, Asp58Tyr, Glu109Lys, Glu112Lys, Ile88Leu, Phe64Ser, Phe84Leu, Pro44Ser, Pro791Ser, Thr80Ala, Val91Ala). The distribution by ethnicities showed that 378 (48,2%) patients identified themselves as white, 306 (39%) as mixed, 72 (9,2%) as black and 5 (0,6%) as Asiatic (2,9% unknown).
Conclusion: Our data highlights the importance to suspect of ATTRv in patients with suggestive symptoms and signs, regardless of ethnicity. We also call attention to the epidemiological importance of the TTRVal142Ile  and  the TTRIleVal variants in the Brazilian population and to the  large variety of TTR mutations causing this disease.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Wilson Marques Junior
FMRP-USP
Ribeirão Preto, SP, Brazil

**Main Body of the Abstract**
Introduction: Although characterized as a Portuguese descent country, the Brazilian population is multi racial, including mainly Portuguese and African descents, but also Italians, Spanish, Japanese, Germans and Dutch, with minor contribution of other countries.  Due to the huge Portuguese importance, the TTRVal50Met was thought to be the only mutation, but this concept gradually changed. In this study we characterized the distribution of ATTRv in Brazil and its ethnical aspects.
Methods: This cohort was descriptive, retrospective and enrolled a group of patients harboring suggestive phenotypes and at-risk family members of index cases with the TTR pathogenic mutation from 19 Brazilian centers.
Results: We enrolled a total of 784 patients belonging to 261 families. 385 (49,1%) were male. The disease was manifest in 435 (55,5%) of patients and one third (33,3%) were asymptomatic carriers (11,2% unknown). The three most frequent TTR mutation were TTRpVal50Met (53,6%), TTRpVal142Ile (31,6%) and TTRIle127Val (8,4%). Other 13 mutations account for equal or less than 1% (Ala60Thr, Arg123His, Asp58Ala, Asp58Tyr, Glu109Lys, Glu112Lys, Ile88Leu, Phe64Ser, Phe84Leu, Pro44Ser, Pro791Ser, Thr80Ala, Val91Ala). The distribution by ethnicities showed that 378 (48,2%) patients identified themselves as white, 306 (39%) as mixed, 72 (9,2%) as black and 5 (0,6%) as Asiatic (2,9% unknown).
```
Conclusion: Our data highlights the importance to suspect of ATTRv in patients with suggestive symptoms and signs, regardless of ethnicity. We also call attention to the epidemiological importance of the TTRVal142Ile  and  the TTRIleVal variants in the Brazilian population and to the  large variety of TTR mutations causing this disease.
```



ATTRv distribution in a continental multiracial country PB41 (#439)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.